Genetic polycythemia

Genetic polycythemia (also known as familial polycythemia or hereditary polycythemia) is a group of rare inherited conditions characterized by an abnormal increase in the number of red blood cells (erythrocytosis). Unlike acquired polycythemia vera, which is caused by somatic mutations in the JAK2 gene and is classified as a myeloproliferative neoplasm, genetic polycythemia results from germline mutations that affect oxygen sensing pathways or hemoglobin oxygen affinity. The condition primarily affects the hematologic system, leading to elevated hemoglobin and hematocrit levels, which increases blood viscosity and can impair normal blood flow. Several distinct genetic causes have been identified under this umbrella classification. These include mutations in the erythropoietin receptor gene (EPOR), the VHL gene (associated with Chuvash polycythemia and other VHL-related erythrocytosis), the EGLN1 (PHD2) gene, the EPAS1 (HIF2A) gene, and genes encoding hemoglobin subunits that result in high oxygen affinity hemoglobin variants. Mutations in these genes disrupt the normal regulation of erythropoietin production or red blood cell formation, leading to overproduction of red blood cells. Symptoms may include headaches, dizziness, facial plethora (reddish complexion), fatigue, visual disturbances, and an increased risk of thromboembolic events such as stroke or deep vein thrombosis due to elevated blood viscosity. Management of genetic polycythemia depends on the underlying genetic cause and severity of symptoms. Therapeutic phlebotomy (periodic blood removal) is the mainstay of treatment to reduce hematocrit levels and decrease the risk of thrombotic complications. Low-dose aspirin may be recommended in some patients to reduce clotting risk. Unlike polycythemia vera, cytoreductive therapies are generally not indicated. Prognosis varies depending on the specific genetic subtype; some forms, such as EPOR-related polycythemia, tend to have a relatively benign course, while VHL-related forms may carry a higher risk of thrombotic events. Genetic counseling is recommended for affected families to clarify the inheritance pattern and recurrence risk.

Common questions about Genetic polycythemia